Company: SCLXW
Filing Date: 2025-11-14
Form Type: 424B3
Source: 0001193125-25-283337
Chunk: 96

Company: Scilex Holding Co
Filing Date: 2025-11-14
Form: 424B3
Chunk 96
---
   |
| Other                                   |     |                                  |   512 |     |      |     — |   |     |            |   512 |   |
| Total R&D Discovery Project             |     |                                  |   528 |     |      |     — |   |     |            |   528 |   |
| Total Research and Development Expenses |     | $                                | 3,899 |     | $    | 2,349 |   |     | $          | 1,550 |   |

Research and development expenses for the three months ended September 30, 2025 and 2024 were $3.9 million and $2.3 million, respectively. The increase was primarily attributed to higher development cost related to SP-102 and additional expenses related to KDS2010 to Scilex Bio. Selling, General and Administrative Expenses Selling, general and administrative expenses for the three months ended September 30, 2025 and 2024 were $188.8 million and $29.7 million, respectively. The increase of approximately $159.1 million was primarily due to a $140.0 million increase related to issuance costs for reverse recapitalization with Denali, a $24.5 million increase in advisory and financing expenses, a $1.8 million increase related to issuance costs for September 2025 Warrants, a $3.0 million increase in expense related to the shares of Common Stock issuable to Tumim Stone Capital, LLC (“Tumim”) in connection with the Company’s equity line of credit with Tumim and a $2.5 million decrease in other expenses, partially offset by a $5.3 million decrease in rebate expenses related to future shipments of the Additional Product (as defined in the Satisfaction Agreement) under the Satisfaction Agreement, a $1.4 million decrease in legal fees, a $1.7 million decrease in travel expenses, a $1.4 million decrease in marketing expenses, a $1.4 million decrease in personnel expense, a $1.2 million decrease in allowances for expected credit losses on accounts receivable, and a $0.3 million decrease in insurance costs in the three months ended September 30, 2025.

<div align='center'>56</div>

Intangible Amortization Expense

Intangible amortization expense for each of the three months ended September 30, 2025 and 2024 was $1.0 million.

Legal Settlements

Legal settlements for the